SCHEMBL6435012

SCHEMBL6435012

CN1CCN([C@H]2CC[C@H](n3nc(-c4ccc(O)cc4)c4c(N)ncnc43)CC2)CC1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 12/20 0.75
LCK P06239 11/20 0.75
TEK Q02763 11/20 0.75
KDR P35968 6/20 0.74
BTK Q06187 2/20 0.74
EGFR P00533 8/20 0.62
ERBB2 P04626 6/20 0.62
IGF1R P08069 6/20 0.62
ERBB3 P21860 6/20 0.62
ERBB4 Q15303 6/20 0.62
NUDT14 O95848 1/20 0.62
NUDT5 Q9UKK9 1/20 0.62
LIMK1 P53667 1/20 0.58
LIMK2 P53671 1/20 0.58
PIK3CD O00329 1/20 0.56
ABL1 P00519 1/20 0.56
HCK P08631 1/20 0.56
PIK3CA P42336 1/20 0.56
PIK3CB P42338 1/20 0.56
MTOR P42345 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5804632 1.00 SRC (0.75) SRCLCKTEKKDRBTK
SCHEMBL5804624 1.00 SRC (0.75) SRCLCKTEKKDRBTK
SCHEMBL4818329 0.92 LCK (0.77) SRCLCKTEKKDRBTK
SCHEMBL4818337 0.92 LCK (0.77) SRCLCKTEKKDRBTK
SCHEMBL5822885 0.92 LCK (0.77) SRCLCKTEKKDRBTK
SCHEMBL6431294 0.88 LCK (0.72) SRCLCKTEKKDRBTK
SCHEMBL5823077 0.88 LCK (0.58) SRCLCKTEKKDRBTK
SCHEMBL6432210 0.88 LCK (0.71) SRCLCKTEKKDRBTK
SCHEMBL6432204 0.88 LCK (0.71) SRCLCKTEKKDRBTK
SCHEMBL4826886 0.87 LCK (0.71) SRCLCKTEKKDRBTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
US-6660744-B1 Kinase inhibitors ABBOTT GMBH & CO. KG (DE) 2003-12-09 US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 SRC 1834/4885LCK 1011/4885TEK 1657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.